| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Pathology, Beth Israel Hospital and Harvard Medical School, and the Charles A. Dana Research Institute, Beth Israel Hospital, Boston, Massachusetts 02215 [D. R. S., L. V. D. W., H. F. D.], and The Monsanto Company, St. Louis, Missouri 63167 [D. T. C., J. F.]
Rodent and human tumor cell lines secrete a potent vascular permeability factor (VPF) which causes a rapid and substantial increase in microvascular permeability to plasma proteins without causing mast cell degranulation, or endothelial cell damage or without exciting an inflammatory cell infiltrate [D. R. Senger, S. J. Galli, A. M. Dvorak, C. A. Perruzzi, V. S. Harvey, and H. F. Dvorak. Science (Wash. DC), 219: 983–985, 1983; D. R. Senger, C. A. Perruzzi, J. Feder, and H. F. Dvorak. Cancer Res., 46: 5629–5632, 1986]. VPF now has been purified to homogeneity from guinea pig tumor cell culture medium; it is a Mr 34,000–43,000 protein, and a NH2-terminal amino acid sequence has been derived. A synthetic peptide corresponding to amino acid residues 1–24 of the native protein was used to raise rabbit antibodies which bind all of the vessel permeability-increasing activity secreted by guinea pig tumor cells and which stain purified VPF on immunoblots. These findings establish that this NH2-terminal amino acid sequence was derived from the permeability factor. Homology searches found no identity or close similarity between VPF NH2-terminal sequence and database sequences, indicating that VPF is distinct from other proteins for which sequence data are available. In particular, no sequence similarity was found between tumor-secreted VPF and other mediators of increased vessel permeability including plasma and glandular kallikreins.
1 This work was supported by USPHS Grant CA 43967 (D.R.S.) awarded by the National Cancer Institute, Department of Health and Human Services, USPHS Grant GM 36812 (L.V.D.W.) awarded by the National Institute of General Medical Sciences, Grant JFRA-198 (L.V.D.W.) from the American Cancer Society, and by a grant from the Monsanto Company.
2 To whom requests for reprints should be addressed, % Department of Pathology, Beth Israel Hospital, 330 Brookline Avenue, Boston, MA 02215.
Received 1/30/89.
Revised 9/20/89.
This article has been cited by other articles:
|
|
 |
|
  J. J. Wroblewski, J. A. Wells III, A. P. Adamis, R. R. Buggage, E. T. Cunningham Jr, M. Goldbaum, D. R. Guyer, B. Katz, M. M. Altaweel, and for the Pegaptanib in Central Retinal Vein Occlusi Pegaptanib Sodium for Macular Edema Secondary to Central Retinal Vein Occlusion Arch Ophthalmol, April 1, 2009; 127(4): 374 - 380. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Qiu, H. Bevan, S. Weeraperuma, D. Wratting, D. Murphy, C. R Neal, D. O. Bates, and S. J. Harper Mammary alveolar development during lactation is inhibited by the endogenous antiangiogenic growth factor isoform, VEGF165b FASEB J, April 1, 2008; 22(4): 1104 - 1112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T C Kreutzer, C S Alge, A H Wolf, D Kook, J Burger, R Strauss, C Kunze, C Haritoglou, A Kampik, and S Priglinger Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion Br J Ophthalmol, March 1, 2008; 92(3): 351 - 355. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Horvath and Y. Zhou Transmyocardial Laser Revascularization and Extravascular Angiogenetic Techniques to Increase Myocardial Blood Flow Card. Surg. Adult, January 1, 2008; 3(2008): 733 - 752. [Full Text]
|
|
|
|
 |
|
 J. Kusari, S. Zhou, E. Padillo, K. G. Clarke, and D. W. Gil Effect of Memantine on Neuroretinal Function and Retinal Vascular Changes of Streptozotocin-Induced Diabetic Rats Invest. Ophthalmol. Vis. Sci., November 1, 2007; 48(11): 5152 - 5159. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Amrite, S. P. Ayalasomayajula, N. P. S. Cheruvu, and U. B. Kompella Single Periocular Injection of Celecoxib-PLGA Microparticles Inhibits Diabetes-Induced Elevations in Retinal PGE2, VEGF, and Vascular Leakage. Invest. Ophthalmol. Vis. Sci., March 1, 2006; 47(3): 1149 - 1160. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C-M Lai, S A Dunlop, L A May, M Gorbatov, M Brankov, W-Y Shen, N Binz, Y K. Lai, C E Graham, C J Barry, et al. Generation of transgenic mice with mild and severe retinal neovascularisation Br J Ophthalmol, July 1, 2005; 89(7): 911 - 916. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Cao, A. Hong, H. Schulten, and M. J. Post Update on therapeutic neovascularization Cardiovasc Res, February 15, 2005; 65(3): 639 - 648. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Podar and K. C. Anderson The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications Blood, February 15, 2005; 105(4): 1383 - 1395. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. X. Zhang, J.-x. Ma, J. Sima, Y. Chen, M. S. Hu, A. Ottlecz, and G. N. Lambrou Genetic Difference in Susceptibility to the Blood-Retina Barrier Breakdown in Diabetes and Oxygen-Induced Retinopathy Am. J. Pathol., January 1, 2005; 166(1): 313 - 321. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Ferrara Vascular Endothelial Growth Factor: Basic Science and Clinical Progress Endocr. Rev., August 1, 2004; 25(4): 581 - 611. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Rudolfsson, P. Wikstrom, A. Jonsson, O. Collin, and A. Bergh Hormonal Regulation and Functional Role of Vascular Endothelial Growth Factor A in the Rat Testis Biol Reprod, February 1, 2004; 70(2): 340 - 347. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Koyama, E. Sato, A. Tsukadaira, M. Haniuda, H. Numanami, M. Kurai, S. Nagai, and T. Izumi Vascular endothelial growth factor mRNA and protein expression in airway epithelial cell lines in vitro Eur. Respir. J., December 1, 2002; 20(6): 1449 - 1456. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. F. Dvorak Vascular Permeability Factor/Vascular Endothelial Growth Factor: A Critical Cytokine in Tumor Angiogenesis and a Potential Target for Diagnosis and Therapy J. Clin. Oncol., November 1, 2002; 20(21): 4368 - 4380. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Flyvbjerg, F. Dagnaes-Hansen, A. S. De Vriese, B. F. Schrijvers, R. G. Tilton, and R. Rasch Amelioration of Long-Term Renal Changes in Obese Type 2 Diabetic Mice by a Neutralizing Vascular Endothelial Growth Factor Antibody Diabetes, October 1, 2002; 51(10): 3090 - 3094. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Koyama, E. Sato, M. Haniuda, H. Numanami, S. Nagai, and T. Izumi Decreased Level of Vascular Endothelial Growth Factor in Bronchoalveolar Lavage Fluid of Normal Smokers and Patients with Pulmonary Fibrosis Am. J. Respir. Crit. Care Med., August 1, 2002; 166(3): 382 - 385. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Beliveau, D. Gingras, E. A. Kruger, S. Lamy, P. Sirois, B. Simard, M. G. Sirois, L. Tranqui, F. Baffert, E. Beaulieu, et al. The Antiangiogenic Agent Neovastat (Ae-941) Inhibits Vascular Endothelial Growth Factor-mediated Biological Effects Clin. Cancer Res., April 1, 2002; 8(4): 1242 - 1250. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Senger, C. A. Perruzzi, M. Streit, V. E. Koteliansky, A. R. de Fougerolles, and M. Detmar The {alpha}1{beta}1 and {alpha}2{beta}1 Integrins Provide Critical Support for Vascular Endothelial Growth Factor Signaling, Endothelial Cell Migration, and Tumor Angiogenesis Am. J. Pathol., January 1, 2002; 160(1): 195 - 204. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E. Epstein, S. Fuchs, Y. F. Zhou, R. Baffour, and R. Kornowski Therapeutic interventions for enhancing collateral development by administration of growth factors: basic principles, early results and potential hazards Cardiovasc Res, February 16, 2001; 49(3): 532 - 542. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Suzuma, Y. Hata, A. Clermont, F. Pokras, S. L. Rook, K. Suzuma, E. P. Feener, and L. P. Aiello Cyclic Stretch and Hypertension Induce Retinal Expression of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor--2: Potential Mechanisms for Exacerbation of Diabetic Retinopathy by Hypertension Diabetes, February 1, 2001; 50(2): 444 - 454. [Abstract] [Full Text]
|
|
|
|
|
|
W. Philipp, L. Speicher, and C. Humpel Expression of Vascular Endothelial Growth Factor and Its Receptors in Inflamed and Vascularized Human Corneas Invest. Ophthalmol. Vis. Sci., August 1, 2000; 41(9): 2514 - 2522. [Abstract] [Full Text]
|
|
|
|
|
|
D. R. Senger and L. Van De Water VEGF Expression by Epithelial and Stromal Cell Compartments : Resolving a Controversy Am. J. Pathol., July 1, 2000; 157(1): 1 - 3. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Li, Y.-F. Chen, S. S. Kelpke, S. Oparil, and J. A. Thompson Estrogen Attenuates Integrin-{beta}3-Dependent Adventitial Fibroblast Migration After Inhibition of Osteopontin Production in Vascular Smooth Muscle Cells Circulation, June 27, 2000; 101(25): 2949 - 2955. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Borre, B. Nerstrom, and J. Overgaard Association between Immunohistochemical Expression of Vascular Endothelial Growth Factor (VEGF), VEGF-expressing Neuroendocrine-differentiated Tumor Cells, and Outcome in Prostate Cancer Patients Subjected to Watchful Waiting Clin. Cancer Res., May 1, 2000; 6(5): 1882 - 1890. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kono, N. Koide, Y. Hama, H. Kitahara, H. Nakano, J.-i. Suzuki, M. Isobe, and J. Amano EXPRESSION OF VASCULAR ENDOTHELIAL GROWTH FACTOR AND ANGIOGENESIS IN CARDIAC MYXOMA: A STUDY OF FIFTEEN PATIENTS J. Thorac. Cardiovasc. Surg., January 1, 2000; 119(1): 101 - 107. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Detmar, P. Velasco, L. Richard, K. P. Claffey, M. Streit, L. Riccardi, M. Skobe, and L. F. Brown Expression of Vascular Endothelial Growth Factor Induces an Invasive Phenotype in Human Squamous Cell Carcinomas Am. J. Pathol., January 1, 2000; 156(1): 159 - 167. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Bleuel, S. Popp, N. E. Fusenig, E. J. Stanbridge, and P. Boukamp Tumor suppression in human skin carcinoma cells by chromosome 15 transfer or thrombospondin-1 overexpression through halted tumor vascularization PNAS, March 2, 1999; 96(5): 2065 - 2070. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T.-H. Lee, T. Rhim, and S. S. Kim Prothrombin Kringle-2 Domain Has a Growth Inhibitory Activity against Basic Fibroblast Growth Factor-stimulated Capillary Endothelial Cells J. Biol. Chem., October 30, 1998; 273(44): 28805 - 28812. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. P. Claffey, S.-C. Shih, A. Mullen, S. Dziennis, J. L. Cusick, K. R. Abrams, S. W. Lee, and M. Detmar Identification of a Human VPF/VEGF 3' Untranslated Region Mediating Hypoxia-induced mRNA Stability Mol. Biol. Cell, February 1, 1998; 9(2): 469 - 481. [Abstract] [Full Text]
|
|
|
|
 |
|
 L. L. Couper, S. R. Bryant, J. Eldrup-Jorgensen, C. E. Bredenberg, and V. Lindner Vascular Endothelial Growth Factor Increases the Mitogenic Response to Fibroblast Growth Factor-2 in Vascular Smooth Muscle Cells In Vivo via Expression of fms-Like Tyrosine Kinase-1 Circ. Res., December 19, 1997; 81(6): 932 - 939. [Abstract] [Full Text]
|
|
|
|
 |
|
 E. Y. Soh, Q.-Y. Duh, S. A. Sobhi, D. M. Young, H. D. Epstein, M. G. Wong, Y. K. Garcia, Y. D. Min, R. F. Grossman, A. E. Siperstein, et al. Vascular Endothelial Growth Factor Expression Is Higher in Differentiated Thyroid Cancer than in Normal or Benign Thyroid J. Clin. Endocrinol. Metab., November 1, 1997; 82(11): 3741 - 3747. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Gruden, S. Thomas, D. Burt, S. Lane, G. Chusney, S. Sacks, and G. Viberti Mechanical stretch induces vascular permeability factor in human mesangial cells: Mechanisms of signal transduction PNAS, October 28, 1997; 94(22): 12112 - 12116. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Cao, A. Chen, S. S. A. An, R.-W. Ji, D. Davidson, Y. Cao, and M. Llinas Kringle 5 of Plasminogen is a Novel Inhibitor of Endothelial Cell Growth J. Biol. Chem., September 5, 1997; 272(36): 22924 - 22928. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. O SCHLINGEMANN and V. W M VAN HINSBERGH Role of vascular permeability factor/vascular endothelial growth factor in eye disease Br J Ophthalmol, June 1, 1997; 81(6): 501 - 512. [Full Text] [PDF]
|
|
|
|
|
|
R. Mohle, D. Green, M. A. S. Moore, R. L. Nachman, and S. Rafii Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets PNAS, January 21, 1997; 94(2): 663 - 668. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Cao, RichardW. Ji, D. Davidson, J. Schaller, D. Marti, S. Sohndel, StephenG. McCance, MichaelS. O'Reilly, M. Llinas, and J. Folkman Kringle Domains of Human Angiostatin. CHARACTERIZATION OF THE ANTI-PROLIFERATIVE ACTIVITY ON ENDOTHELIAL CELLS J. Biol. Chem., November 15, 1996; 271(46): 29461 - 29467. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Brauchle, J. Funk, P. Kind, and S. Werner Ultraviolet B and H2O2 Are Potent Inducers of Vascular Endothelial Growth Factor Expression in Cultured Keratinocytes J. Biol. Chem., September 6, 1996; 271(36): 21793 - 21797. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. A. Lutty, D. S. McLeod, C. Merges, A. Diggs, and J. Plouet Localization of Vascular Endothelial Growth Factor in Human Retina and Choroid Arch Ophthalmol, August 1, 1996; 114(8): 971 - 977. [Abstract] [PDF]
|
|
|
|
|
|
Y. Cao, H. Chen, L. Zhou, M.-K. Chiang, B. Anand-Apte, J. A. Weatherbee, Y. Wang, F. Fang, J. G. Flanagan, and M. L.-S. Tsang Heterodimers of Placenta Growth Factor/Vascular Endothelial Growth Factor J. Biol. Chem., February 9, 1996; 271(6): 3154 - 3162. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. P. Aiello, J. M. Northrup, B. A. Keyt, H. Takagi, and M. A. Iwamoto Hypoxic Regulation of Vascular Endothelial Growth Factor in Retinal Cells Arch Ophthalmol, December 1, 1995; 113(12): 1538 - 1544. [Abstract] [PDF]
|
|
|
|
|
|
M. Nomura, S.-i. Yamagishi, S.-i. Harada, Y. Hayashi, T. Yamashima, J. Yamashita, and H. Yamamoto Possible Participation of Autocrine and Paracrine Vascular Endothelial Growth Factors in Hypoxia-induced Proliferation of Endothelial Cells and Pericytes J. Biol. Chem., November 24, 1995; 270(47): 28316 - 28324. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. W. Stepnick, M. K. Peterson, C. Bodgan, J. Davis, J. Wasman, and K. Mailer Effects of Tumor Necrosis Factor {alpha} and Vascular Permeability Factor on Neovascularization of the Rabbit Ear Flap Arch Otolaryngol Head Neck Surg, June 1, 1995; 121(6): 667 - 672. [Abstract] [PDF]
|
|
|
|
 |
|
 B. Williams, A. Q. Baker, B. Gallacher, and D. Lodwick Angiotensin II Increases Vascular Permeability Factor Gene Expression by Human Vascular Smooth Muscle Cells Hypertension, May 1, 1995; 25(5): 913 - 917. [Abstract] [Full Text]
|
|
|
|
 |
|
 W. Roberts and G. Palade Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor J. Cell Sci., January 6, 1995; 108(6): 2369 - 2379. [Abstract] [PDF]
|
|
|
|
 |
|
 C de Vries, J. Escobedo, H Ueno, K Houck, N Ferrara, and L. Williams The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor Science, February 21, 1992; 255(5047): 989 - 991. [Abstract] [PDF]
|
|
|
|
|
|
I. Suzuma, K. Suzuma, K. Ueki, Y. Hata, E. P. Feener, G. L. King, and L. P. Aiello Stretch-induced Retinal Vascular Endothelial Growth Factor Expression Is Mediated by Phosphatidylinositol 3-Kinase and Protein Kinase C (PKC)-zeta but Not by Stretch-induced ERK1/2, Akt, Ras, or Classical/Novel PKC Pathways J. Biol. Chem., January 4, 2002; 277(2): 1047 - 1057. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Peng, L. Zhang, L. Drysdale, and G.-H. Fong The transcription factor EPAS-1/hypoxia-inducible factor 2alpha plays an important role in vascular remodeling PNAS, July 18, 2000; 97(15): 8386 - 8391. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
